SEARCH

SEARCH BY CITATION

References

  • BRADLEY, P.P., PRIEBAT, D.A., CHRISTENSEN, R.D. & ROTHSTEIN, G. (1982). Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J. Invest. Dermatol., 78, 206209.
  • CHIANG, N., GRONERT, K., CLISH, C.B., O'BRIEN, J.A., FREEMAN, M.W. & SERHAN, C.N. (1999). Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J. Clin. Invest., 104, 309316.
  • CHIANG, N., GRONERT, K., QIU, F.-H. & SERHAN, C.N. (2000). Lipoxin A4 receptor. In: Cytokine Reference, ed. OPPENHEIM, J.J. & FELDMANN, M. pp. 22192233. London : Academic Press.
  • CLÀRIA, J. & SERHAN, C.N. (1995). Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl. Acad. Sci. U.S.A., 92, 94759479.
  • CLISH, C.B., O'BRIEN, J.A., GRONERT, K., STAHL, G.L., PETASIS, N.A. & SERHAN, C.N. (1999). Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc. Natl. Acad. Sci. U.S.A., 96, 82478252.
  • DEVCHAND, P.R., ARITA, M., HONG, S., BANNENBERG, G.L., MOUSSIGNAC, R.-L., GRONERT, K. & SERHAN, C.N. (2003). Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host-defense. FASEB J., 17, 652659.
  • EDENIUS, C., KUMLIN, M., BJÖRK, T., ÄNGGÅRD, E. & LINDGREN, J.A. (1990). Lipoxin formation in human nasal polyps and bronchial tissue. FEBS Lett., 272, 2528.
  • FILEP, J.G., ZOUKI, C., PETASIS, N.A., HACHICHA, M. & SERHAN, C.N. (1999). Anti-inflammatory actions of lipoxin A4 stable analogs are demonstrable in human whole blood: modulation of leukocyte adhesion molecules and inhibition of neutrophil-endothelial interactions. Blood, 94, 41324142.
  • FIORUCCI, S., SANTUCCI, L., WALLACE, J.L., SARDINA, M., ROMANO, M., DEL SOLDATO, P. & MORELLI, A. (2003). Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc. Natl. Acad. Sci. U.S.A., 100, 1093710941.
  • GALLIN, J.L. & SNYDERMAN, R. (1999). Inflammation. Basic Principles and Clinical Correlates. Philadelphia : Lippincott Williams & Wilkins.
  • GAVINS, F.N., YONA, S., KAMAL, A.M., FLOWER, R.J. & PERRETTI, M. (2003). Leukocyte antiadhesive actions of annexin 1: ALXR- and FPR-related anti-inflammatory mechanisms. Blood, 101, 41404147.
  • GEWIRTZ, A.T., COLLIER-HYAMS, L.S., YOUNG, A.N., KUCHARZIK, T., GUILFORD, W.J., PARKINSON, J.F., WILLIAMS, I.R., NEISH, A.S. & MADARA, J.L. (2002). Lipoxin A4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J. Immunol., 168, 52605267.
  • GILROY, D.W., COLVILLE-NASH, P.R., WILLIS, D., CHIVERS, J., PAUL-CLARK, M.J. & WILLOUGHBY, D.A. (1999). Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med., 5, 698701.
  • GILROY, D.W., LAWRENCE, T., PERRETTI, M. & ROSSI, A.G. (2004). Inflammatory resolution: new opportunities for drug discovery. Nat. Rev. Drug. Discov., 3, 401416.
  • GUILFORD, W.J., BAUMAN, J.G., SKUBALLA, W., BAUER, S., WEI, G.P., DAVEY, D., SCHAEFER, C., MALLARI, C., TERKELSEN, J., TSENG, J.-L., SHEN, J., SUBRAMANYAM, B., SCHOTTELIUS, A.J. & PARKINSON, J.F. (2004). Novel 3-oxa lipoxin A4 analogs with enhanced chemical and metabolic stability have anti-inflammatory activity in vivo. J. Med. Chem., 47, 21572165.
  • LAWRENCE, T., WILLOUGHBY, D.A. & GILROY, D.W. (2002). Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat. Immunol., 2, 787795.
  • LEE, T.H., CREA, A.E., GANT, V., SPUR, B.W., MARRON, B.E., NICOLAOU, K.C., REARDON, E., BREZINSKI, M. & SERHAN, C.N. (1990). Identification of lipoxin A4 and its relationship to the sulfidopeptide leukotrienes C4, D4, and E4 in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases. Am. Rev. Resp. Dis., 141, 14531458.
  • LEVY, B.D., CLISH, C.B., SCHMIDT, B., GRONERT, K. & SERHAN, C.N. (2001). Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol., 2, 612619.
  • MADDOX, J.F., COLGAN, S.P., CLISH, C.B., PETASIS, N.A., FOKIN, V.V. & SERHAN, C.N. (1998). Lipoxin B4 regulates human monocyte/neutrophil adherence and motility: design of stable lipoxin B4 analogs with increased biologic activity. FASEB J., 12, 487494.
  • MADDOX, J.F., HACHICHA, M., TAKANO, T., PETASIS, N.A., FOKIN, V.V. & SERHAN, C.N. (1997). Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor. J. Biol. Chem., 272, 69726978.
  • MIYASAKA, C.K., MENDONCA, J.R., NISHIYAMA, A., ALVES DE SOUZA, J.A., PIRES DE MELO, M., PITHON-CURI, T.C. & CURI, R. (2001). Comparative effects of fish oil given by gavage and fish oil-enriched diet in leukocytes. Life Sci., 69, 17391751.
  • PACE-ASCIAK, C.R. (1989). Mass Spectra of Prostaglandins and Related Products. New York : Raven Press.
  • PERRETTI, M., CHIANG, N., LA, M., FIERRO, I.M., MARULLO, S., GETTING, S.J., SOLITO, E. & SERHAN, C.N. (2002). Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat. Med., 8, 12961302.
  • ROBERTS II, L.J. & MORROW, J.D. (2001). Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, ed. HARDMAN, J.G. & LIMBIRD, L.E. pp. 687731. New York : McGraw-Hill.
  • SCALIA, R., GEFEN, J., PETASIS, N.A., SERHAN, C.N. & LEFER, A.M. (1997). Lipoxin A4 stable analogs inhibit leukocyte rolling and adherence in the rat mesenteric microvasculature: role of P-selectin. Proc. Natl. Acad. Sci. U.S.A., 94, 99679972.
  • SCHOTTELIUS, A.J., GIESEN, C., ASADULLAH, K., FIERRO, I.M., COLGAN, S.P., BAUMAN, J., GUILFORD, W., PEREZ, H.D. & PARKINSON, J.F. (2002). An aspirin-triggered lipoxin A4 stable analog displays a unique topical anti-inflammatory profile. J. Immunol., 169, 70637070.
  • SERHAN, C.N. (1991). In: Advances in Rheumatology and Inflammation, ed. HEDQVIST, P., KALDEN, J.R., MULLER-PEDDINGHAUS, R. & ROBINSON, D.R. pp. 141153. Basel : Eular.
  • SERHAN, C.N. (2001). Lipoxins and aspirin-triggered 15-epi-lipoxins are endogenous components of antiinflammation: emergence of the counterregulatory side. Arch. Immunol. Ther. Exp., 49, 177188.
  • SERHAN, C.N., FIORE, S., BREZINSKI, D.A. & LYNCH, S. (1993). Lipoxin A4 metabolism by differentiated HL-60 cells and human monocytes: conversion to novel 15-oxo and dihydro products. Biochemistry, 32, 63136319.
  • SERHAN, C.N., MADDOX, J.F., PETASIS, N.A., AKRITOPOULOU-ZANZE, I., PAPAYIANNI, A., BRADY, H.R., COLGAN, S.P. & MADARA, J.L. (1995). Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry, 34, 1460914615.
  • SERHAN, C.N., NICOLAOU, K.C., WEBBER, S.E., VEALE, C.A., DAHLÉN, S.E., PUUSTINEN, T.J. & SAMUELSSON, B. (1986). Lipoxin A. Stereochemistry and biosynthesis. J. Biol. Chem., 261, 1634016345.
  • SERHAN, C.N. & OLIW, E. (2001). Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways. J. Clin. Invest., 107, 14811489.
  • SIMCHOWITZ, L., FIORE, S. & SERHAN, C.N. (1994). Carrier-mediated transport of lipoxin A4 in human neutrophils. Am. J. Physiol., 267, C1525C1534.
  • TAKANO, T., CLISH, C.B., GRONERT, K., PETASIS, N. & SERHAN, C.N. (1998). Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogs. J. Clin. Invest., 101, 819826.
  • TAKANO, T., FIORE, S., MADDOX, J.F., BRADY, H.R., PETASIS, N.A. & SERHAN, C.N. (1997). Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogs are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J. Exp. Med., 185, 16931704.
  • WALLACE, J.L., CHAPMAN, K. & MCKNIGHT, W. (1999). Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation. Br. J. Pharmacol., 126, 12001204.